Palonosetron | compare suppliers & send inquiries for free
Looking for Palonosetron 135729-56-5?
- API | Excipient name:
- Palonosetron
- Synonyms:
- Palonosetron, Palonosetronum
- Cas Number:
- 135729-56-5
- DrugBank number:
- DB00377
- Unique Ingredient Identifier:
- 29WVV1OJ05
About Palonosetron
Here, you can find what Palonosetron is used for, in short. Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.
Not sure if this is the exact product you're looking for? Contact the supplier by using the send inquiry button.
Palonosetron manufacturers | traders | suppliers
We have 17 companies offering Palonosetron from 6 different countries.
Get in contact with the supplier of your choice:
- MSN Labs. from India
- Aurobindo from India
- Shandong Keyuan from China
- Dr. Reddy's from India
- Neuland Labs. from India
- Emcure Pharma from India
- Glenmark Pharma from India
- Teva from Israel
- Tyche Industries from India
- Wavelength from Israel
- Rolabo Outsourcing from Spain
- Qilu Pharma from China
- Cipla from India
- ALP PHARM from China
- USV from India
- Helsinn Advanced Synthesis SA from Switzerland
- Wockhardt from India
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.